paclitaxel has been researched along with asp3026 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doihara, H; Furutani, T; Fushiki, H; Konagai, S; Kondoh, Y; Kudoh, M; Kuromitsu, S; Mori, K; Mori, M; Saito, R; Sakagami, H; Shimada, I; Shindou, N; Soga, T; Ueno, Y | 1 |
1 other study(ies) available for paclitaxel and asp3026
| Article | Year |
|---|---|
The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
Topics: 3T3 Cells; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Drug Synergism; Glutamates; Guanine; Humans; Immunoblotting; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Molecular Structure; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Sulfones; Survival Analysis; Triazines; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |